Media

Oncopeptides – First patients in Spain to be treated with Pepaxti

Oncopeptides – Invitation to presentation of the Q1 report 2024

Vicore Announces Positive Final Results from the Phase 2a AIR Trial Demonstrating Buloxibutid Improves Lung Function Over 36 Weeks in Patients with Idiopathic Pulmonary Fibrosis

Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte

Oncopeptides presents new data highlighting treatment benefits of Pepaxti in high-risk multiple myeloma patients at the COMy Congress

Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update

Vicore Expands and Strengthens its Board of Directors

Spruce Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates

Fusion Pharmaceuticals Announces First Patient Dosed In The Phase 2 Portion Of The AlphaBreak Trial Evaluating FPI-2265 In Metastatic Castration-Resistant Prostate Cancer

Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024